Skip to content

    Laxmi Dental

    LAXMIDENTL
    Healthcare·27 May 2025
    Management Summary

    Laxmi Dental reported its highest ever revenues and profits for FY25, driven by strong growth in both domestic and international markets, and particularly in Aligner Solutions. Q4 FY25 saw some aberrations, including a decline in the domestic lab business, but the company remains focused on digitalization, brand-building, and exploring inorganic growth opportunities. The company's debt-to-equity ratio is healthy, and it plans to deploy IPO proceeds for capex and strategic initiatives.

    Highlights

    5
    • FY25 Revenue of ₹239 crores, up 23.5% YoY, highest ever.

    • FY25 PAT of ₹32 crores, up 26.2% YoY, highest ever.

    • Digital penetration increased to 64% from 49% during FY25.

    • IDS event participation generated significant global leads across all three businesses.

    • Debt-to-equity ratio improved to 0.06, indicating a strong balance sheet post-IPO.

    Concerns

    3
    • Q4 FY25 results featured 'some aberrations' impacting performance.

    • Domestic lab business de-grew by 14% in Q4, with overall FY25 growth at 8% for this segment.

    • Employee cost in Q4 FY25 was ₹24.4 crores, including ESOP expenses of ₹1.75 crores.

    What Changed2

    vs Q1 FY26

    Guidance items4 → 5 (+1)Q&A highlights5 → 8 (+3)
    Key financials

    Metrics

    10

    Periods

    2

    Q4 FY25

    5
    • Revenue
      ₹61 Cr
      YoY+10.2%
    • Gross Margin
      78.7%
      YoY+1%
    • EBITDA
      ₹9.5 Cr
    • Adjusted EBITDA
      ₹12.4 Cr
    • PAT
      ₹4.3 Cr

    FY25

    5
    • Revenue
      ₹239 Cr
      YoY+23.5%
    • EBITDA
      ₹42 Cr
      YoY+75.8%
    • Adjusted EBITDA
      ₹52 Cr
    • PAT
      ₹32 Cr
      YoY+26.2%
    • PAT Margin
      13.3%

    Segment breakdown

    Revenue ContributionGrowthFY25 Revenue
    Dental Laboratory Business62%19%
    Aligner Solutions32%41%₹77 Cr
    Kids-e-Dental₹26 Cr
    Heatmap· 3 shared metrics

    Capital allocation

    3
    high confidence
    CategoryHeadline
    Capex

    ₹68 crores

    IPO proceeds

    Debt

    Debt disclosed

    Liquidity

    Cash ₹100 crores

    Cash sitting on books from IPO proceeds, available for capex and inorganic growth.

    Guidance & targets

    5
    CategoryTargetPriority
    Revenue
    Revenue Growth
    20-25%
    High
    Digital Penetration
    Digital Penetration
    90-95%, hopefully 100%
    Medium
    Advertising & Promotion
    A&P as % of Sales
    ~5%
    High
    Profitability
    Margin Expansion
    definitely scope for expansion
    Low
    ESOP Expenses
    Total ESOP Expenses
    ₹14 crores
    High

    Digital Penetration Progress

    next quarter / ongoing
    Current64%
    TargetMoving towards 90-95%, hopefully 100%

    Why it matters

    Digitalization is a key strategic focus for efficiency and market reach, impacting overall growth and margins.

    Digitalization is the way to go in industry in dentistry and we are investing in the scanner to be able to deploy it aggressively across our dental partners. ... our goal is to go towards 90%-95%, hopefully 100% digitization.

    How to verify

    guidance_and_targets[category='Digital Penetration']

    Risks & concerns

    3
    RiskSeverity

    Aberrations in Q4 results

    Management noted 'some aberrations' in Q4 results, which impacted performance.Management acknowledged

    medium

    Domestic lab business de-growth

    The domestic lab business de-grew by 14% in Q4 and showed only 8% growth for FY25, raising concerns about competitive intensity.Analyst acknowledged

    medium

    US tariff situation

    Management acknowledged initial concerns about US tariffs but stated they have managed the situation well, seeing strong international growth, especially in the US.Management acknowledged

    low

    Q&A highlights

    8

    “So, on the lab side, like I said while the domestic, you have seen an X percentage. We would like to say that we see it as an overall scenario and especially in the last two quarters or maybe one quarter, if you see two quarters starting today with this tariff situation in the US, we have really managed to be there, make sure that the tariff has not affected the international operations on our side.”

    Analyst highlighted a significant de-growth in the domestic lab business in Q4 (-14%) and slow FY25 growth (8%), questioning competitive pressures, which management attributed to overall market scenario and strategic focus on digitalization rather than direct competition.

    asked by Nikhil Mathur

    2 min read6 chapters

    Detailed Narrative

    01

    Strong FY25 Performance with Record Revenues and Profits

    Laxmi Dental Limited achieved its highest ever revenues and profits in FY25, with revenue reaching ₹239 crores, marking a 23.5% year-on-year growth from ₹194 crores in the previous year. PAT also hit a record high of ₹32 crores, growing 26.2% year-on-year, with a PAT margin of 13.3%. The company's EBITDA for FY25 stood at ₹42 crores, demonstrating a robust 75.8% year-on-year growth, reflecting strong operational performance throughout the year.

    02

    Q4 FY25 Performance and Aberrations

    For Q4 FY25, the company reported a revenue of ₹61 crores, an increase of 10.2% year-on-year from ₹55 crores. Gross margin improved by one percentage point year-on-year to 78.7%. However, management noted 'some aberrations' in the quarter, including promotional expenses of approximately ₹45 lakhs for the IDS Germany dental show and ESOP expenses of ₹1.75 crores within the total employee cost of ₹24.4 crores. Adjusted EBITDA for the quarter was ₹12.4 crores, and PAT was ₹4.3 crores.

    03

    Strategic Focus on Digitalization and Innovation

    Digitalization remains a core strategic pillar, with the company's digital penetration increasing to 64% in FY25 from 49%. The goal is to further increase this to 90-95%, potentially 100%. Laxmi Dental is investing in intraoral scanners and advanced machine equipment to aggressively deploy digital solutions across its dental partners. The company is also exploring the integration of AI capabilities to enhance productivity and improve the experience for dentists and customers.

    04

    Segmental Growth and Aligner Business Strategy

    In FY25, the dental laboratory business contributed 62% of total revenue and grew by 19%. The Aligner Solutions segment showed strong momentum, growing 41% year-on-year and contributing 32% of the revenue, totaling ₹77 crores. The Kids-e-Dental business generated ₹26 crores in revenue with an EBITDA of ₹15.5 crores and PAT of ₹12 crores, and recently received regulatory clearance for Singapore, with more international clearances expected soon. The aligner business operates on a dentist-led model, differentiating it from D2C competitors, and offers a flexible 'pay-as-you-go' model.

    05

    Capital Allocation and Inorganic Growth Outlook

    Post-IPO, the company has a strong balance sheet with a debt-to-equity ratio of 0.06. Management has repaid debt and plans to deploy ₹68 crores from IPO proceeds towards capex, primarily for new machine equipment and intraoral scanners. While a small amount was spent in FY25, deployment will accelerate in the current year. Laxmi Dental is also actively looking for select inorganic growth opportunities that offer strong synergy and leverage future growth.

    06

    International Dental Show (IDS) Impact and Global Reach

    The company's participation in the International Dental Show (IDS) in Germany, a premier dental event held once every two years, was highly impactful. Laxmi Dental had three booths, showcasing products across its businesses to global dentists, labs, and distributors. This event generated significant leads from multiple countries, which the company is now processing and expects to translate into good results within the current financial year, with momentum carrying forward for the next two years due to registration timelines.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.